CLTI 范式转变:膝下动脉腔内治疗临床试验设计与终点的启示
本文讨论从临界肢体缺血(CLI)到慢性肢体威胁性缺血(CLTI)的范式转变对临床试验终点的影响,指出血流动力学指标和病变通畅率等传统终点不能充分反映 CLTI 复杂性及以患者为中心的结局,并提出改良的临床驱动靶病变血运重建(CD-TLR)定义,涵盖流入道、靶病变和流出道病变。
要点
- 传统终点如血流动力学指标和病变通畅率不足以反映 CLTI 复杂性和患者相关结局。
- 改良 CD-TLR 定义综合评估流入道、靶病变和流出道血管健康。
- 应优先采用保肢、伤口愈合和功能结局等患者相关终点而非仅替代终点。
核心结论
- 改良 CD-TLR 定义可能更好反映现代 CLTI 管理策略并提高试验结果的临床相关性。
主要发现
- 传统终点如血流动力学指标和病变通畅率不能充分反映 CLTI 复杂性或以患者为中心的结局。
- 传统 CD-TLR 可能不足以指导临床决策。
关键数值与推荐
- 提出改良 CD-TLR 定义,涵盖流入道、靶病变和流出道病变。
临床怎么用
- 临床应重视保肢、伤口愈合和功能结局等患者相关终点,而非仅依赖替代终点。
- 使用改良 CD-TLR 定义可更全面评估血管健康并支持治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The evolution from critical limb ischemia to chronic limb-threatening ischemia (CLTI) necessitates a reevaluation of clinical trial endpoints. Traditional measures like hemodynamic indices and lesion patency inadequately reflect CLTI complexity or patient-centered outcomes. This article explores the limitations of conventional endpoints and proposes a modified definition of clinically-driven target lesion (TL) revascularization (CD-TLR) that addresses inflow, TL, and outflow disease. By incorporating a more comprehensive assessment of vascular health and prioritizing patient-relevant outcomes, this modified CD-TLR definition may better reflect modern CLTI management strategies and improve clinical relevance of trial results in this challenging patient population.Clinical ImpactThe evolution from CLI to CLTI requires reassessing how we measure treatment success in clinical trials. This review identifies why traditional endpoints like hemodynamic indices, lesion patency, and CD-TLR may not adequately inform clinical decision-making. The importance of measuring outcomes that directly impact patient quality of life will help clinicians better evaluate and apply clinical trial results. An emphasis on limb salvage, wound healing, and functional outcomes, rather than surrogate endpoints alone, will lead to more informed treatment decisions and improved CLTI management strategies.
引用
- Mustapha JA, Jacob R, Miller LE, et al. The CLTI Paradigm Shift: Implications for Clinical Trial Design and Endpoints in Endovascular Management of Infrapopliteal Disease. J Endovasc Ther. 2025. PMID: 40874834. doi:10.1177/15266028251363541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。